Market Newsdesk

SHANGHAI, China, July 02, 2025 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced that the final offering price for its previously announced China REIT (“C-REIT”) initial public offering (“IPO”) on the Shanghai Stock Exchange is RMB 3.00 per unit. The final offering price was determined following completion of the institutional bookbuilding, which was 166 times over-subscribed. The C-REIT will issue 800,000,000 units in total, representing 100% of units in issue on completion of the IPO. The gross proceeds to be received by the C-REIT is RMB 2,400 million.

At the final offering price, the implied EV / EBITDA, based on the projected EBITDA for 2026 for the C-REIT contained in the offering memorandum of RMB 141.8 million, is 16.9 times. At the final offering price, the implied dividend yield per unit, based on the projected cash flow available for distribution for 2026 contained in the offering memorandum of RMB 124.8 million, is 5.2 per cent.

GDS will enter into an agreement to sell to the C-REIT a 100% equity interest in a project company which holds stabilized data center assets for a total enterprise value of approximately RMB 2,319 million. On completion of the sale, GDS will receive total net cash proceeds of approximately RMB 2,111 million, comprising equity consideration and dividend of existing cash, net of tax and certain other transaction costs. In addition, GDS will de-consolidate approximately RMB 62 million of net debt and other liabilities. GDS will reinvest RMB 480 million to subscribe for 20% of the units issued by the C-REIT in the IPO.

GDS will continue to operate and manage the underlying data center assets under a services agreement with the project company transferred to the C-REIT, pursuant to which GDS will receive recurring annual fee income of approximately RMB 5 million.

About GDS Holdings Limited

GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698) is a leading developer and operator of high-performance data centers in China. The Company’s facilities are strategically located in and around primary economic hubs where demand for high-performance data center services is concentrated. The Company’s data centers have large net floor area, high power capacity, density and efficiency, and multiple redundancies across all critical systems. GDS is carrier and cloud-neutral, which enables its customers to access the major telecommunications networks, as well as the largest PRC and global public clouds, which are hosted in many of its facilities. The Company offers co-location and a suite of value-added services, including managed hybrid cloud services through direct private connection to leading public clouds, managed network services, and, where required, the resale of public cloud services. The Company has a 24-year track record of service delivery, successfully fulfilling the requirements of some of the largest and most demanding customers for outsourced data center services in China. The Company’s customer base consists predominantly of hyperscale cloud service providers, large internet companies, financial institutions, telecommunications carriers, IT service providers, and large domestic private sector and multinational corporations. The Company also holds a non-controlling 35.6% equity interest in DayOne Data Centers Limited which develops and operates data centers in International markets.

For investor and media inquiries, please contact:

GDS Holdings Limited

Laura Chen
Phone: +86 (21) 2029-2203
Email: [email protected]

Piacente Financial Communications

Ross Warner
Phone: +86 (10) 6508-0677
Email: [email protected]

Brandi Piacente
Phone: +1 (212) 481-2050
Email: [email protected]

GDS Holdings Limited

BRIDGEWATER, N.J., July 02, 2025 (GLOBE NEWSWIRE) — VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today provided a program update for VYN202 following the clinical hold issued by the U.S. Food and Drug Administration (FDA) in April for the Company’s Phase 1b clinical trial in the treatment of moderate-to-severe plaque psoriasis. VYN202 is an oral small molecule BD2-selective bromodomain and extra-terminal domain (BET) inhibitor that is being developed for the treatment of immune-mediated diseases.   

VYN202 Program Update

In April, the FDA placed a clinical hold on the Company’s Phase 1b trial following an observation of testicular toxicity in dogs from a non-clinical toxicology study of VYN202. A No-Observed-Adverse-Effect Level (NOAEL) was established covering all clinical doses in females. The FDA has lifted the clinical hold for female patients on the 0.25 mg and 0.5 mg doses in this Phase 1b psoriasis trial. The 1 mg dose was not included at this time in the revised protocol submitted to the FDA due to its lower toxicological safety margin as compared to the 0.25 mg and 0.5 mg doses. Sufficient data from a 12-week non-clinical toxicology study of VYN202 in dogs would be required in order to resume the trial in male clinical subjects, and the design of this toxicology study has been agreed upon with the FDA.

Following the clinical hold, VYNE made the decision to unblind the clinical data from the subjects who were enrolled in the study (VYN202 treated: n=6 across 0.25 mg, 0.5 mg and 1 mg doses; Placebo treated: n=1), the results of which are described below.

The Company believes that the totality of the data from this study, together with promising results from multiple preclinical models, support the continued advancement of VYN202 into serious, immune-mediated diseases with limited effective treatment options. Based on this assessment, the Company will no longer enroll patients in the Phase 1b psoriasis study, extending the Company’s expected cash runway into the fourth quarter of 2026. VYNE expects to provide further updates on its plans for the VYN202 program following the release of top-line results from the ongoing Phase 2b study of its lead candidate repibresib gel (formerly VYN201), a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo.

Preliminary Data from Phase 1b Trial

(n=7 enrolled: VYN202: n=6 across 0.25 mg, 0.5 mg and 1 mg doses; Placebo: n=1)

Please visit the Events and Presentations site on the VYNE Therapeutics corporate website for data presentation.   

Safety and tolerability results

• No TESAEs or discontinuations due to a clinical TEAE
• No treatment interruptions due to a clinical TEAE
• No grades of thrombocytopenia, neutropenia or lymphocytopenia

Exploratory efficacy and serum biomarker results

• All subjects treated with VYN202 had an improvement in signs and symptoms of disease, including scalp psoriasis
  • Improvement in PASI scores ranged from ~27% reduction after 1 week of treatment to ~90% reduction at week 8.
• Improvements (reduction) in serum cytokine levels involved in the pathogenesis of plaque psoriasis were observed in subjects treated with VYN202 for greater than 1 week, including IL17A, IL17F, IL19 and IL22 ranging from -17% to -83%. There was no change in these serum cytokines for the subject receiving placebo.

• Two subjects enrolled co-presented with psoriatic arthritis (n=1 treated with VYN202 0.5mg; n=1 treated with placebo)
  • Subject treated with VYN202 0.5 mg reported a four-point improvement in joint pain NRS scale by week 2 which corresponded with a -48% reduction in serum c-reactive protein level, a biomarker associated with psoriatic arthritis and other rheumatic diseases.
  • Subject treated with placebo had no improvement in joint pain NRS and no change in serum c-reactive protein levels.

About Repibresib

Repibresib is a pan-bromodomain BET inhibitor designed to be locally administered as a “soft” drug to address diseases involving multiple, diverse inflammatory cell signaling pathways, while providing low systemic exposure. In addition to demonstrating clinical proof-of-concept in vitiligo, repibresib has produced consistent reductions in pro-inflammatory and disease-related biomarkers and improvements in disease severity in several preclinical models (using several different routes of administration).

About VYN202

VYN202 is an innovative, oral small molecule BET inhibitor that has potential class-leading selectivity and potency for BD2 vs. BD1. By maximizing BD2 selectivity, VYNE believes VYN202 has the potential to be a differentiated, more conveniently administered, non-biologic treatment option for both acute control and chronic management of immuno-inflammatory indications, in which the damaging effects of unrestricted inflammatory signaling activity are common.

About VYNE Therapeutics Inc. 
VYNE is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. VYNE’s unique and proprietary BET inhibitors, which comprise its InhiBET™ platform, are designed to overcome limitations of early generation BET inhibitors by leveraging alternative routes of administration and enhanced selectivity.

For more information about VYNE Therapeutics Inc. or its product candidates, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.

Investor Relations:

John Fraunces
LifeSci Advisors, LLC
917-355-2395
[email protected] 

Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
[email protected] 

Cautionary Statement Regarding Forward-Looking Statements 
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical development of VYN202, the potential benefits of VYN202, the timing of reporting results for the Phase 2b study of repibresib, VYNE’s expected cash runway, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE’s ability to successfully develop its product candidates; the timing of commencement of future preclinical studies and clinical trials; VYNE’s ability to complete and receive favorable results from clinical trials of its product candidates; VYNE’s ability to obtain additional funding, either through equity or debt financing transactions or collaboration arrangements; and VYNE’s ability to comply with various regulations applicable to its business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and VYNE’s other filings from time to time with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.

Third-party products and company names mentioned herein may be the trademarks of their respective owners.

• 
  Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 satellite locations to enroll patients in BriaCell’s pivotal Phase 3 study
  
• 
  BriaCell’s Phase 3 study currently has 58 active clinical sites across 15 states, including Smilow Cancer Hospital, Los Angeles Cancer Network, University of Arizona, DHR Health Oncology Institute, Sylvester Comprehensive Cancer Center, Cancer Care Northwest, Hematology Oncology Associates of Fredericksburg, Northwestern University, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, and Texas Oncology-Baylor Charles A. Sammons Cancer Center
  

PHILADELPHIA and VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of two key large cancer centers to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612): Los Angeles Cancer Network and Smilow Cancer Hospital at New Haven. Each has 15 satellite locations. BriaCell anticipates completing patient enrollment in late 2025 or early 2026 and may report top line data as early as H1-2026.

BriaCell’s pivotal Phase 3 clinical study is evaluating BriaCell’s lead clinical candidate, Bria-IMT™, plus immune check point inhibitor (CPI) versus physician’s choice in advanced metastatic breast cancer (Bria-ABC).

“Clinical investigator interest in our Phase 3 study has exceeded our expectations which has significantly expanded patient access to our treatment,” stated Giuseppe Del Priore, MD, MPH, BriaCell’s Chief Medical Officer. “This strong engagement reflects both the urgent unmet need in metastatic breast cancer and the dedication of our clinical partners.”

Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival (OS) in patients treated with the Bria-IMT combination regimen versus those treated with physician’s choice as the primary endpoint. Positive results of the pivotal Phase 3 study could result in full approval and marketing authorization for Bria-IMT in MBC patients. BriaCell recently (ASCO 2025) announced positive Phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received FDA Fast Track designation.

For additional information on BriaCell’s pivotal Phase 3 study of Bria-IMT and an immune check point inhibitor in metastatic breast cancer, please visit ClinicalTrials.gov NCT06072612.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about the anticipated completion date of patient enrollment for the Company’s ongoing pivotal Phase 3 clinical study; the anticipated timeline for reporting top line data for the Company’s pivotal Phase 3 study; the timing and results of interim data; and the final results of the pivotal Phase 3 study, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:

William V. Williams, MD
President & CEO
1-888-485-6340
[email protected] 

Investor Relations Contact:

[email protected]

WASHINGTON, July 02, 2025 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that it will release financial results for the second quarter ended June 30, 2025 before the New York market opens on Thursday, July 24, 2025.

A conference call will be held to discuss these financial results on Thursday, July 24, 2025, at 9:00 a.m. Eastern Time and will be hosted by senior management.

The conference call will be simulcast live on the Internet and can be accessed by logging onto the Company’s investor relations website. A replay of the webcast will be available on the Company’s investor relations website for 90 days.

About FTI Consulting

FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 33 countries and territories as of March 31, 2025. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.70 billion in revenues during fiscal year 2024. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.

555 12^th Street NW
Washington, DC 20004
+1.202.312.9100

Investor Contact:

Mollie Hawkes
+1.617.747.1791
[email protected]

RESTON, Va., July 02, 2025 (GLOBE NEWSWIRE) — Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services and project management firm, today announced it has entered into a definitive purchase agreement to acquire e3i Engineers, a Boston, Massachusetts-based firm specializing in the design of data centers, energy infrastructure and emerging technology applications. The acquisition enhances Bowman’s ability to support clients with increasingly complex inside-the-data-center engineering needs, building on its existing strength in site planning, civil design and utility infrastructure.

e3i Engineers has built a solid reputation over the past decade for its work supporting data centers and other mission-critical infrastructure across the U.S. The firm’s portfolio includes more than 3.2 million square feet of designed data center space, including projects supporting AI, high density and hyperscale requirements. e3i has been an early adopter of technical innovations including direct-to-chip (DtoC) cooling, known as cold plate technology, that minimizes transformation and distribution losses and costs. They also provide turnkey engineering solutions for fuel cells, battery storage and microgrids for resilient, low-carbon energy systems.

“The acquisition of e3i is a strategic step forward as we expand our footprint beyond site and civil infrastructure and further into the heart of the data center,” said Gary Bowman, founder and CEO of Bowman. “e3i has been instrumental in the evolution of AI-optimized data center design where their technical offerings have improved performance standards across mission-critical infrastructure. Their forward-thinking approach has advanced how data centers are engineered. e3i brings specialized expertise that strengthens our technical offering for clients building AI-enabled, high-density and energy-intensive environments. These capabilities complement our platform and help position us for long-term growth in data, digital and distributed energy markets.”

“We’ve always believed that engineering should be a force for what’s next,” said William Leuci, president of e3i. “Like Bowman, we are a partner-driven firm which has enabled us to deliver unique and cost-effective solutions to our clients for the past decade. Bowman brings scale, reach and resources to amplify our impact across fast growing markets. The combination of our technology-led expertise with their multidisciplinary platform creates a differentiated value proposition in the design of high-performance, future-ready infrastructure.”

Financed with a combination of cash, seller notes and a convertible note, the acquisition conforms with previously discussed target multiples and operating metrics. Bowman anticipates the acquisition will initially operate at an annualized net service billing run rate of approximately $2.0 million. More detailed information on M&A activities, pipeline and guidance updates are provided in connection with quarterly and annual communications.

About e3i Engineers, Inc.

Based in Boston, Massachusetts, e3i Engineers, Inc. is a specialized engineering and technology solutions firm dedicated to delivering technology solutions, design and project management services for data centers, sustainable and natural resources, mission critical and other technologically complex projects. The company has served both private and public clients throughout the U.S., U.K. and South America. For more information, visit https://e3i-inc.com..

About Bowman Consulting Group Ltd.

Headquartered in Reston, Virginia, Bowman is a national engineering services firm delivering infrastructure, technology and project management solutions to customers who own, develop and maintain the built environment. With over 2,400 employees in 100 locations throughout the U.S., Bowman provides a variety of planning, engineering, geospatial, construction management, commissioning, environmental consulting, land procurement and other technical services to customers operating in a diverse set of regulated end markets. Bowman trades on the Nasdaq under the symbol BWMN. For more information, visit bowman.com or investors.bowman.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, including statements regarding our future results of operations and financial position, business strategy and plans and objectives for future operations, are forward-looking statements and represent our views as of the date of this press release. The words “anticipate”, “believe”, “continue”, “estimate”, “expect”, “intend”, “may”, “will”, “goal” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to several assumptions and risks and uncertainties, many of which involve factors or circumstances that are beyond our control that could affect our financial results. The Company cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements contained in this news release. Such factors include: (a) changes in demand from the local and state government and private clients that we serve; (b) general economic conditions, nationally and globally, and their effect on the market for our services; (c) competitive pressures and trends in our industry and our ability to successfully compete with our competitors; (d) changes in laws, regulations, or policies; and (e) the “Risk Factors” set forth in the Company’s most recent SEC filings. Considering these risks, uncertainties and assumptions, the future events and trends discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in any forward-looking statements. Except as required by law, we are under no obligation to update these forward-looking statements after the date of this press release, or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.

Investor Relations Contact:

Betsy Patterson
[email protected]

General Media Contact:

Christina Nichols
[email protected]

CLEVELAND, July 02, 2025 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $155 million on June 27, 2025.

Including net proceeds from the sale of the PRV, the Company reported that unaudited cash, cash equivalents, restricted cash and short-term investments as of June 30, 2025 were approximately $225 million.

“We have reached another key milestone: the successful sale of our PRV has closed,” said Joe Vazzano, Chief Financial Officer of Abeona. “The PRV proceeds, combined with our existing cash, provides Abeona with robust financial flexibility, ensuring over two years of operating capital for sustained growth without the need for further capital infusion and prior to accounting for ZEVASKYN sales. We anticipate the first ZEVASKYN patient treatment in Q3 2025, with profitability projected for early 2026.”

Abeona was awarded the PRV by the U.S. Food and Drug Administration (FDA) in April 2025 in connection with the FDA’s approval of ZEVASKYN™ (prademagene zamikeracel), the first and only U.S. approved autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN™ (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN^TM, Abeona Assist^TM, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

Forward-Looking Statements

This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, our ability to commercialize ZEVASKYN; the therapeutic potential of ZEVASKYN, whether the unmet need and market opportunity for ZEVASKYN are consistent with the Company’s expectations, continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with and inspections from the FDA or other regulatory agencies, including those relating to preclinical programs; our ability to obtain necessary regulatory approvals; the impact of any changes in the financial markets or global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
[email protected]

VANCOUVER, British Columbia, July 02, 2025 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology company specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), and enterprise SaaS, has signed an offer to acquire a California-based civil engineering and land surveying firm with a well established history of operations. This marks ZenaTech’s first proposed transaction in the US West Coast or Southwest region, creating a strategic entry point into California ─ a high-value market for drone-based precision agriculture due to a massive agriculture economy, crop diversity, labor and water challenges, and an openness to innovation.

With a commercial, construction and sustainability solution customer base and a deep regional presence, the proposed acquisition positions ZenaTech to scale its Drone as a Service or DaaS survey operations. It also provides significant opportunity to expand into California’s wine and agriculture sectors using advanced drone capabilities including aerial imaging, precision spraying, irrigation analytics, and wildfire detection and monitoring in high-risk areas.

“This proposed acquisition is more than just our first Southwest region location — it’s a strategic foothold into a high-value, high-growth state for precision agriculture,” said Shaun Passley, Ph.D., CEO of ZenaTech. “The firm is a natural fit to help execute our growth strategy for crop health monitoring and precision spraying to serve viticulture, large estates, and commercial farming operations across California.”

With the global agricultural drone market projected to reach USD 10.3 billion by 2030, driven by rising demand for precision technologies in farming, California stands out as a key growth region as well as being home to nearly 90% of all US vineyard acreage. Considering California’s mounting climate and agricultural challenges, ZenaTech’s AI-powered autonomous drone solutions offer timely, scalable innovation that serves the needs of commercial enterprises, cooperatives, agriculture consultants, and public sector stakeholders.

ZenaTech’s Drone as a Service (DaaS) business model offers both business and government customers reduced costs and convenience to utilize drones to streamline legacy processes and manual tasks such as inspections, surveying, maintenance, precision agriculture and inventory management ─ there is no need to purchase drone hardware and software, find a drone pilot, manage maintenance and operation, or acquire regulatory approvals. The model also offers scalability to use more often or less often based on business needs and utilizes ZenaDrone’s multifunction AI autonomous drones.

The company has closed six acquisitions across the US to date as part of its DaaS business model and strategy and has announced it plans to complete approximately 20 more in the next 12 months.

About ZenaTech

ZenaTech (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company specializing in AI drone, Drone as a Service (DaaS), enterprise SaaS and Quantum Computing solutions for mission-critical business applications. Since 2017, the Company has leveraged its software development expertise and grown its drone design and manufacturing capabilities through ZenaDrone, to innovate and improve customer inspection, monitoring, safety, security, compliance, and surveying processes. With enterprise software customers using branded solutions in law enforcement, health, government, and industrial sectors, and drones being implemented in these plus agriculture, defense, and logistics sectors, ZenaTech’s portfolio of solutions helps drive exceptional operational efficiencies, accuracy, and cost savings. The Company operates through seven global offices in North America, Europe, Taiwan, and UAE, and is growing a DaaS business model and additional US locations, and global partner network.

About ZenaDrone

ZenaDrone, a wholly owned subsidiary of ZenaTech, develops and manufactures autonomous business drone solutions that can incorporate machine learning software, AI, predictive modeling, Quantum Computing, and other software and hardware innovations. Created to revolutionize the hemp farming sector, its specialization has grown to multifunctional drone solutions for industrial surveillance, monitoring, inspection, tracking, process automation and defense applications. Currently, the ZenaDrone 1000 drone is used for crop management applications in agriculture and critical field cargo applications in the defense sector, the IQ Nano indoor drone is used for inventory management and security in the warehouse and logistics sectors, and the IQ Square is an indoor/outdoor drone designed for land survey and inspections use in commercial and defense sectors.

Contacts for more information:

Company, Investors and Media:

Linda Montgomery

ZenaTech

312-241-1415

[email protected]

Investors:

Michael Mason

CORE IR

[email protected]

Safe Harbor

This press release and related comments by management of ZenaTech, Inc. include “forward-looking statements” within the meaning of U.S. federal securities laws and applicable Canadian securities laws. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. This forward-looking information relates to future events or future performance of ZenaTech and reflects management’s expectations and projections regarding ZenaTech’s growth, results of operations, performance, and business prospects and opportunities. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. In some cases, forward-looking information can be identified by terminology such as “may”, “will”, “should”, “expect”, “plan”, “anticipate”, “aim”, “seek”, “is/are likely to”, “believe”, “estimate”, “predict”, “potential”, “continue” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking information in this document includes, but is not limited to ZenaTech’s expectations regarding its revenue, expenses, production, operations, costs, cash flows, and future growth; expectations with respect to future production costs and capacity; ZenaTech’s ability to deliver products to the market as currently contemplated, including its drone products including ZenaDrone 1000 and IQ Nano; ZenaTech’s anticipated cash needs and it’s needs for additional financing; ZenaTech’s intention to grow the business and its operations and execution risk; expectations with respect to future operations and costs; the volatility of stock prices and market conditions in the industries in which ZenaTech operates; political, economic, environmental, tax, security, and other risks associated with operating in emerging markets; regulatory risks; unfavorable publicity or consumer perception; difficulty in forecasting industry trends; the ability to hire key personnel; the competitive conditions of the industry and the competitive and business strategies of ZenaTech; ZenaTech’s expected business objectives for the next twelve months; ZenaTech’s ability to obtain additional funds through the sale of equity or debt commitments; investment capital and market share; the ability to complete any contemplated acquisitions; changes in the target markets; market uncertainty; ability to access additional capital, including through the listing of its securities in various jurisdictions; management of growth (plans and timing for expansion); patent infringement; litigation; applicable laws, regulations, and any amendments affecting the business of ZenaTech. 

COLUMBIA, Md. , July 02, 2025 (GLOBE NEWSWIRE) — Rekor Systems, Inc. (NASDAQ: REKR) (the “Company), a leader in developing and implementing state-of-the-art roadway intelligence technology, today announced the extension of its Rekor Command® contract with the Central Texas Regional Mobility Authority (Mobility Authority). The $1.4 million, 5-year agreement reflects the Mobility Authority’s ongoing commitment to evaluate and deploy advanced technologies to enhance incident detection, accelerate response times, and improve roadway safety across Central Texas toll roads.

Initially placed in service in 2021, Rekor Command® serves as a powerful force multiplier for the Mobility Authority’s Traffic Incident Management team, delivering real-time insights and enabling seamless coordination across one of the busiest tolling networks in the region. The Mobility Authority currently operates 60 miles of heavily traveled toll roads—with more mileage being added as new projects come online—and has consistently prioritized the need for faster, more comprehensive visibility into roadway activity.

“At the end of the day, Rekor Command® has made our operators’ lives easier,” said Fabiola Bowers, Assistant Director of Operations – Traffic and Safety for the Mobility Authority. “They work hundreds of incidents a month, so if we can make their days easier with a platform that’s easy to use, it means something. Additionally, the ability to detect quickly means we can provide help to the people involved in the incident more quickly, clear incidents more efficiently, and get people on their way more quickly. That assists not only the individuals involved in the incident, but also those driving through the area. At the end of the day, that’s what it’s all about. Keeping people safe and moving.”

Proven Results Driving Continued Investment

The Mobility Authority’s implementation of Rekor Command® has produced measurable results, including:

• 324% increase in incident detection
• 11-minute faster average response time
• 641 incidents detected monthly, on average
• Seamless integration with public notification systems and multi-agency collaboration
• Advanced analytics that identify high-risk areas for proactive safety interventions

The contract incorporates enhanced features such as:

• Driver Connect: Enables bi-directional communication with drivers and delivers real-time road condition updates directly to vehicles.
• Traffic Impact: AI-powered predictive insights, allowing the Mobility Authority to identify severe incidents and respond more quickly and effectively to traffic impacts and incidents

Rekor Command®: Powering the Future of Toll Road Operations

Fast and accurate incident detection, response, and resolution are critical. The Mobility Authority’s renewed investment underscores the value Rekor brings to this customer segment, which is increasingly focused on delivering safer, smarter, and more responsive roadway infrastructure.

Rekor Command® enables toll road operators to move beyond traditional incident management. The platform provides real-time situational awareness, advanced analytics, and seamless coordination tools, transforming how traffic operations teams monitor roadways, respond to emergencies, and engage with the public.

Supporting Regional Growth with Smarter Tools

With over 35 major infrastructure projects planned across Central Texas through 2032, the Mobility Authority and its regional partners, including the TxDOT Austin District, launched the Construction Partnership Program (CPP). Rekor Command®, along with Rekor’s Incident Detection API and Work Zone Activity API, will support CPP’s mission to reduce congestion, improve safety, and coordinate across agencies during this historic development phase.

“Motivation among toll road authorities is especially high – drivers are paying for a premium service, and agencies are determined to deliver exceptional roadway performance and reliability. The Mobility Authority’s continued partnership is a testament to Rekor Command’s impact and momentum,” said Paul Mathew Zamsky, General Manager of Rekor Command®. “CTRMA’s leadership demonstrates how public tolling and transportation agencies can innovate to improve safety and mobility at scale. We’re proud to be their technology partner.”

About Rekor Systems, Inc.

Rekor Systems, Inc. (NASDAQ: REKR) is a leader in developing and implementing state-of-the-art roadway intelligence systems using AI-enabled computer vision and machine learning. As a pioneer in the implementation of digital infrastructure, Rekor is collecting, connecting, and organizing the world’s mobility data – laying the foundation for a digitally-enabled operating system for the roadway. With our Rekor One® Roadway Intelligence Engine at the core of our technology, we aggregate and transform trillions of data points into intelligence through proprietary computer vision, machine learning, and big data analytics that power our platforms and applications. Our solutions provide actionable insights that give governments and businesses a comprehensive picture of roadways while providing a collaborative environment that drives the world to be safer, greener, and more efficient. To learn more, please visit our website: https://rekor.ai, and follow Rekor on social media on LinkedIn, X (formerly Twitter), Threads, and Facebook.

Forward-Looking Statements

This press release and its links and attachments contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning Rekor Systems, Incthat involve substantial risks and uncertainties, including particularly statements regarding our future results of operations and financial position, business strategy, prospective products and services, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products and services. These statements involve uncertainties, such as known and unknown risks, and are dependent on other important factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance or achievements we express or imply. For this purpose, any statements that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions described under the sections in our Annual Report on Form 10-K for the year ended December 31, 2024 entitled “Risk Factors” and elsewhere in our Quarterly Reports on Form 10-Q. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Readers are urged to carefully review and consider the various disclosures made in this Press Release and in other documents we file from time to time with the SEC that disclose risks and uncertainties that may affect our business. The forward-looking statements in this Press Release do not reflect the potential impact of any divestiture, merger, acquisition, or other business combination that had not been completed as of the date of this filing. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events, or otherwise.

This press release and its links and attachments contain statements concerning Rekor Systems, Inc.

Media & Investor Relations Contact:
Rekor Systems, Inc.
Charles Degliomini
[email protected]